Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Is Latest Target Of Philadelphia U.S. Attorney's Rx Investigation

This article was originally published in The Pink Sheet Daily

Executive Summary

Investigation into Lilly's marketing and promotional practices is focused on Evista, Prozac and Zyprexa, company says. Subpoenas may reflect Philadelphia prosecutor's interest in PBMs and Federal Employee Health Benefits Program.

You may also be interested in...



AstraZeneca Rx Promotions Subject Of U.S. Attorney Investigation

The Los Angeles U.S. Attorney’s Office is examining the company’s local field promotions.

AstraZeneca Rx Promotions Subject Of U.S. Attorney Investigation

The Los Angeles U.S. Attorney’s Office is examining the company’s local field promotions.

Lilly Rebates Prompt U.S. Attorney Investigation

The Philadelphia U.S. Attorney’s office is investigating Medicaid best price reporting for Zyprexa and several other Lilly products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel